EKF Diagnostics Holdings plc (FRA:LYF)

Market Cap	117.36M +12.7%
Revenue (ttm)	59.11M +2.7%
Net Income	2.43M -66.0%
EPS	0.01 -65.8%
Shares Out	n/a
PE Ratio	48.25
Forward PE	14.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	0.2620
Previous Close	0.2620
Day's Range	0.2620 - 0.2620
52-Week Range	0.2580 - 0.3220
Beta	n/a
RSI	40.30
Earnings Date	Mar 24, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1990
• Employees: 297
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LYF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Financial numbers in GBP